IP Library Granted Patent US 7,572,606
Granted Patent B1
US 7,572,606 · App. 11/517,899 · Granted Aug 11, 2009

Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs

Assignee: Nereus Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,572,606
App. No.
11/517,899
Granted
Aug 11, 2009
Kind
B1
Abstract

Disclosed are methods of modulating biosynthesis of Salinosporamide A and its analogs, which are useful in treating cancer, inflammatory conditions, and/or infectious disease. The methods involve, for example, genetic manipulation, selection of reagents in the fermentation feedstock, and selection of fermentation conditions.

Claims (35)

1. A method of producing a first compound of Formula I,

wherein the dashed lines represent a single or a double bond, wherein R 1 is separately selected from the group consisting of a hydrogen, a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, where n is equal to 1 or 2, and if n is equal to 2, then R 1 can be the same or different;

wherein R 2 is selected from the group consisting of hydrogen, a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl;

wherein R 3 is selected from the group consisting of a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl;

wherein each of E 1 , E 2 , E 3 and E 4 is a substituted or unsubstituted heteroatom;

the method comprising culturing a strain of Salinospora in a saline medium using a feedstock that is deficient in or has an excess of one or more of proprionate, butyrate, or valerate compared to levels of proprionate, butyrate, and valerate found in a medium comprising starch, Hy soy, and yeast in a ratio of 10 g to 4 g to 4 g such that the relative yield of the first compound in comparison to the yield of a second compound of Formula I is substantially different than the relative yield of the first compound in comparison to the yield of the second compound obtained when the strain is cultured in a medium comprising starch, Hy soy, and yeast in a ratio of 10 g to 4 g to 4 g.

2. The method of claim 1 , wherein the first compound has the structure of Formula II:

wherein each R 4 is separately selected from the group consisting of a hydrogen, a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, where m is equal to 1 or 2, and if m is equal to 2, then R 4 can be the same or different; and

wherein E 5 is a substituted or unsubstituted heteroatom.

3. The method of claim 1 , wherein the first compound has the structure of Formula III:

wherein each R 4 is separately selected from the group consisting of a hydrogen, a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, where m is equal to 1 or 2, and if m is equal to 2, then R 4 can be the same or different; and

wherein E 5 is a substituted or unsubstituted heteroatom.

4. The method of claim 1 , wherein the first compound has the structure of Formula IV:

wherein R 5 is separately selected from the group consisting of a hydrogen, a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, where m is equal to 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, and if m is greater than 1, then R 5 can be the same or different; and

wherein E 5 is a substituted or unsubstituted heteroatom.

5. The method of claim 1 , wherein the first compound has the structure of Formula V:

wherein R 5 is separately selected from the group consisting of a hydrogen, a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, where m is equal to 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, and if m is greater than 1, then R 5 can be the same or different; and

wherein E 5 is a substituted or unsubstituted heteroatom.

6. The method of claim 1 , wherein the first compound is the compound of Formula II-16:

7. The method of claim 1 , wherein the other second compound is the compound of Formula II-17:

8. The method of claim 1 , wherein said feedstock is deficient in one or more reagent selected from proprionate, butyrate, and valerate.

9. The method of claim 8 , wherein the reagent is proprionate.

10. The method of claim 8 , wherein the reagent is butyrate.

11. The method of claim 8 , wherein the reagent is valerate.

12. The method of claim 1 , wherein said feedstock comprises an excess of one or more reagent selected from proprionate, butyrate, and valerate.

13. The method of claim 12 , wherein the reagent is proprionate.

14. The method of claim 12 , wherein the reagent is butyrate.

15. The method of claim 12 , wherein the reagent is valerate.

16. The method of claim 1 , wherein said feedstock is deficient in butyrate,

wherein the first compound is the compound of Formula II-16:

and wherein the second compound is the compound of Formula II-17:

17. The method of claim 1 , wherein said feedstock comprises an excess of propionate,

wherein the first compound is the compound of Formula II-20 or the compound of Formula II-29:

18. The method of claim 1 , wherein said feedstock comprises an excess of valerate,

wherein the first compound is the compound of Formula II-30:

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2017
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 041698/0404 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2016
From: HBM VIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCARDERO PARTNER II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 040327/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2013
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 029909/0114 →
SECURITY AGREEMENT Recorded May 21, 2009
From: NEREUS PHARMACEUTICALS, INC.
To: HBM BIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCADERO PARTNERS II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
Reel/Frame 022719/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2006
From: LAM, KIN SING; PALLADINO, MICHAEL; TSUENG, GINGER
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 018576/0863 →
Continuity (3)
Provisional Application 6071540400 · Sep 9, 2005
Provisional Application 6081677100 · Jun 26, 2006
Provisional Application 6081675300 · Jun 26, 2006